Immunome wins Ayala’s Phase III desmoid tumour candidate for $50m

07 Feb 2024
·
Deals
www.pharmaceutical-technology.com
Phase 2Phase 1Clinical ResultDrug ApprovalPhase 3
Immunome will pay $20m upfront and $30m in common stock. A further $37.5m is in line for Ayala if certain milestones are met. Image credit: Shutterstock/PhotobyTawat.
Immunome will acquire rights to two clinical assets from oncology company Ayala PharmaceuAyalas, in a $50m deal.
Immunome covers AL102, a Phase III therapy for desmoid tumour treatment, aAyala PharmaceuticalsL101, currently in Phase II trials for adenoid cystic carcinoma.
Immunome will paAL102m upfront and $30m in commdesmoid tumournding on development and commerciAL101lestones, Ayala is also in line to adenoid cystic carcinoma.
Immunomeoth candidates will transfer hands to Immunome, AL102 is the asset generating the most buzz. The US FAyaland Drug Administration (FDA) only recently approved the first drug for desmoid tumour treatment, when SpringWorks Therapeutics’ Ogsiveo (nirogacestat) secured FDA approval in November 2023.
Now, Immunome says data from clinical trials sImmunomet AL102 could be more effective than Ogsiveo which, liFood and Drug Administration (FDA)a secretase inhibitor.desmoid tumourSpringWorks TherapeuticsOgsiveonirogacestatFDA
See AImmunomegene to secure licence for two HUTCHMED druAL102didatesOgsiveoAL102gamma secretase
IGC PharmInmagenetowards a Phase I study for Alzheimer’s disease
Results from the Phase II portion of the RINGSIDE study demonstrated an objective response rate of 75% at a dose of 1.2mg AL102. According to the FDA, the objective response rate for Ogsiveo was 41%. There have been no head-to-head studies between the two drugs.
IGC Pharmainical journey continues in the ongAlzheimer’s diseaseion of the RINGSIDE study (NCT04871282). The same dose from Phase II is being evaluated in an estimated 192 participants with desmoid tumours. The study’s primary endpoint is progression-free survival after two years.
Desmoid tumours are non-cancerous growths that are estimated to affect 1,650 people in the US. They can be found anywhere in the body and are most common in young adults. Due to their aggressive growth in connective tissue, the tumours can cause pain and disability. The disease is currently treated by surgery or radiation, though the tumours can be difficult to remove.
Immunome’s CEO Clay Siegall said: “As we complete the work required to advance AL102 to NDA submission, our goal is to bring clinical benefit to aFDAnderserved patient population whilOgsiveoating substantial value for stockholders.”
Siegall added that the company plans to investigate AL102’s use in more populations of cancer patients.desmoid tumours
Desmoid tumourstes from Ayala add to another recent acquisition by Immunome. The company acquired a collection of antibody-related assets from Atreca in a deal worth up to $12m in December 2023.tumourspaintumours
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.